Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo

(2013) A. Heine et al.   BLOOD

An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor

(2013) Nicholas G. Wysham et al.   CHEST

Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib

(2013) Rowan Wathes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bilateral Toxoplasmosis Retinitis Associated with Ruxolitinib

(2013) Roger A. Goldberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ruxolitinib for myelofibrosis therapy: current context, pros and cons

(2012) A Pardanani   LEUKEMIA

Foxp3+ regulatory T cells, immune stimulation and host defence against infection

(2011) Jared H. Rowe et al.   IMMUNOLOGY

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

(2011) S Hart et al.   LEUKEMIA

Interleukin-2 receptor downstream events in regulatory T cells: Implications for the choice of immunosuppressive drug therapy

(2010) Robert Zeiser et al.   CELL CYCLE

Autoimmunity and the risk of myeloproliferative neoplasms

(2010) S. Y. Kristinsson et al.   HAEMATOLOGICA

Does auto-immunity contribute to anemia in myeloproliferative neoplasms (MPN)-associated myelofibrosis?

(2010) Giovanni Barosi et al.   LEUKEMIA RESEARCH

Advances in Understanding and Management of Myeloproliferative Neoplasms

(2009) A. M. Vannucchi et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Regulatory T cells exert checks and balances on self tolerance and autoimmunity

(2009) Kajsa Wing et al.   NATURE IMMUNOLOGY